Reza Mahjub

TL;DR: This article focuses on recent advances made within the last 5 years in nanoparticle‐based cancer immunotherapy, including peptide‐ and nucleic acid‐based nanovaccines, nanomedicines containing an immunoadjuvant to activate anti‐tumor immunity, nanoparticle delivery of immune checkpoint inhibitors and the combination of the above approaches.

TL;DR: The results obtained in studies presented in this paper indicate that peptides are promising candidates for targeted cancer therapy, and the challenges of using peptide drugs and ways to overcome these limitations are reviewed.

TL;DR: An overview on microRNAs that are involved in the Aβ cascade and their inhibitory impact on their target mRNAs whose products participate in Aβ clearance is discussed.

TL;DR: Oral insulin in the form of nanoparticles may have similar effects to injectable insulin in increasing the gene expression of IGF1 and IGF2 in rats treated with insulin-loaded trimethyl chitosan nanoparticles.

TL;DR: In vivo results showed the efficacy of insulin-coated nanoparticles as well as commercial insulin in compensated weight loss, FBS and protein levels of IGF-1 and IGF-2 in rats with diabetes mellitus.